BBIO

BBIO

USD

BridgeBio Pharma Inc. Common Stock

$61.000-0.420 (-0.684%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$61.420

Máximo

$61.905

Mínimo

$60.230

Volumen

2.10M

Fundamentos de la Empresa

Capitalización de Mercado

11.8B

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

2.63M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $21.72Actual $61.000Máximo $69.48

Noticias Relacionadas

GlobeNewswire

BridgeBio to Participate in November Investor Conferences

PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that

Ver más
BridgeBio to Participate in November Investor Conferences
GlobeNewswire

BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025

PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, announced today that ten

Ver más
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $90 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma with a Buy and maintains $90 price target.

Ver más
HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $90 Price Target
Analyst Upgrades

Goldman Sachs Maintains Buy on BridgeBio Pharma, Raises Price Target to $100

Goldman Sachs analyst Paul Choi maintains BridgeBio Pharma with a Buy and raises the price target from $55 to $100.

Ver más
Goldman Sachs Maintains Buy on BridgeBio Pharma, Raises Price Target to $100
Analyst Upgrades

TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $95

TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma with a Buy and raises the price target from $60 to $95.

Ver más
TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $95
Analyst Upgrades

Raymond James Reiterates Outperform on BridgeBio Pharma, Raises Price Target to $71

Raymond James analyst Martin Auster reiterates BridgeBio Pharma with a Outperform and raises the price target from $69 to $71.

Analyst Upgrades

Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $110

Cantor Fitzgerald analyst Josh Schimmer maintains BridgeBio Pharma with a Overweight and raises the price target from $100 to $110.

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.